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Sequential overlapping Gag protein-derived oligo- 
peptides of human immunodeficiency virus type 1 (HIV- 
l) 22 to 24 amino acids long, were synthesized and 
tested in vitro for antiviral activity. Two synthetic 
peptides, one derived from the matrix protein p17 
(NPGLLETSEGCRQ, amino acids 47 to 59) and one 
located in the capsid protein p24 (PAATLEEMMTA, 
amino acids 339 to 349) inhibited the production of 
infectious virus when added to HIV-l-infected cultures 
when used in the range of 20 to 200 t~g/ml. As shown by 
thin section electron microscopy, peptide tr atment 
resulted in the release of immature, deformed virus 
particles uggesting that the two peptides interfered with 
assembly and maturation. Other Gag protein-derived 
oligopeptides had little or no influence on virus 
production. To characterize further the functionally 
active regions we synthesized peptide derivatives with 
three consecutive amino acids substituted by alanine; 
they did not cause inhibition. Therefore the regions 
responsible for inhibition were located between amino 
acids 50 to 61 in pl7, and 342 to 350 in p24. These 
observations might lead to the development of a new 
antiviral strategy affecting the late stage of virus 
replication. 
Human immunodeficiency virus type 1 (HIV-1), like 
many other complex enveloped viruses, is formed and 
released in a budding process, which involves a number 
of critical steps (Gelderblom, 1991; Wills & Craven, 
1991). Distinct elements essential for particle formation 
have been localized on the structural proteins of HIV-1 
using different expression systems and electron mi- 
croscopy (Gheysen et al., 1989; Hu et al., 1990; Vernon 
et al., 1991). These essential functions for particle 
formation are potential targets for inhibiting virus 
formation and maturation. The Gag protein is synthe- 
sized in the form of a polyprotein precursor (Pr55gag), 
post-translationally modified at the amino-terminal end 
by myristoylation and endoproteolytically cleaved into 
four large (p17, p24, p7 and p6) and two small (p2 and 
p 1) proteins by the virus-encoded protease (Henderson et 
al., 1990). A variety of functions have been shown for the 
Gag proteins. Through the myristic acid modification the 
Pr55 aaa molecule is targeted to he inner leaflet of the cell 
membrane (Gtttlinger et al., 1988). The interaction of 
the viral genomic RNA with the potential 'zinc finger' 
motif of p7 is essential for packaging the RNA into the 
t Present address: Robert Koch-Institut, Bundesgesundheitsamt, 
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particle (Gorelick et al., 1990; South et al., 1991). 
Cleavage of Pr55 g"g at defined sites by the protease is 
required for maturation and infectivity of the virus 
(Tritch et al., 1991); p6 seems to form the core-envelope 
link facilitating the closure of the core sphere (Gtttlinger 
et al., 1991; Htglund et al., 1991). Furthermore, 
protein-protein teractions are required uring the self- 
assembly process involving the accumulation of Pr55 gag 
at the membrane and the viral core formation. We 
postulated that oligopeptides derived from domains 
participating in protein-protein i teraction during the 
oligomerization of Pr55 gag molecules might inhibit virus 
assembly and maturation. 
In this work we defined amino acid sequences within 
the Pr55 oag protein functionally involved in virus as- 
sembly. For this approach we used a library of synthetic 
peptides, 22 to 24 amino acids in length spanning the 
entire sequence of Pr55 ~"~ (Haist et al., 1992), and 
analysed them for their respective potential to influence 
the assembly process of viral Gag proteins by defining 
their ability to inhibit the release of infectious virus 
particles. The purified peptides were dissolved in PBS 
(pH 7-0) and used at concentrations of 40 to 200 ~tg/ml. 
CD4-positive, HIV-l-negative Jurkat cells were incub- 
ated with various amounts (100 to 1000 TCIDso) of HIV- 
1 (strain HTLV-IIIB; Rather et al., 1985) in microtitre 
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Fig. 1. Inhibition of H lV  production by Gag-specific oligopeptides. (a) 
RT activity in the supernatants of the indicator cell cultures. Jurkat 
cells were infected with 100 TCIDs0 and treated with the 41 Gag- 
derived oligopeptides at concentrations of 40 gg/ml. After 3 days, 
100 gl cell-free supernatant was added to fresh Jurkat cells. After 2 
weeks the supernatant of these cells was analysed for RT activity. 
Numbering refers to the peptide used for treatment of the cell culture. 
RT values of untreated HIV-infected Jurkat cell cultures were used as 
a positive control (virus control, VC), those of uninfected cell cultures 
as a negative control. RT activity with values below twice the negative 
control value was considered negative; this value is indicated by the 
horizontal line. (b) RT activity in supernatants of HIV-l-infected 
Jurkat cells treated with various concentrations (25, 50, 100 and 
200 gg/ml) of peptides 4, 5, 28, 29 and 36 (control peptide without 
effect). (c) RT activity in supernatants of Jurkat cells infected with 
various amounts of HIV-1 (100, 200 and 400 TCID50 ) and treated with 
various concentrations of peptides 4/5 and 28/29. 
plates (1 x 105 cells per well). After 2 h of adsorption the 
sample was removed and replaced by medium supple- 
mented with the different peptides. In a similar way 
chronically HIV-l-infected H9 cells were mixed with 
HIV-negative H9 cells at a 1 : 10 ratio and treated with 
the peptide dilutions at the time point of mixing. HIV- 
infected, peptide-treated cells were screened for toxic 
effects. Uninfected, peptide-treated control cell cultures 
were analysed separately for viability by trypan blue 
exclusion. Three to 4 days after infection 100 gl of cell- 
free culture supernatants was added to fresh Jurkat cells 
and assayed for their infectious virus content. The 
indicator cultures were analysed aily for HIV-induced 
syncytium formation. Reverse transcriptase (RT) activity 
in the cell supernatants was measured after 2 weeks of 
incubation using a microassay according to Gregersen et 
al. (1988). Briefly 100 gl of cell culture supernatant was 
concentrated by polyethylene glycol treatment to 20 gl. 
Enzyme activity was determined by incorporation of 
[aH]thymidine using poly(A) as template/primer. 
Four out of 41 peptides present at concentrations of 
40 gg/ml in HIV-l-infected Jurkat cell supernatants 
reduced infectivity. Two of the peptides (4 and 5) 
comprised sequences of the p17 matrix protein and the 
two other peptides (28 and 29), comprised sequences of 
the p24 capsid protein (Fig. 1 a, Table 1). The 'indicator 
cultures' were monitored daily for c.p.e, and 
[3H]thymidine incorporation was used for determination 
of the levels of RT in the supernatants after 2 weeks of 
incubation. This long period of incubation of the 
supernatants from peptide-treated cells with new cell 
cultures was chosen to allow detection of traces of 
infectious HIV due to replication. Levels of HIV-specific 
RT reflect the concentration of infectious virus in 
biological samples (Land et al., 1989); these were reduced 
in the peptide-treated c lls by about 100-fold in com- 
parison to the untreated control (Table 1). The highest 
reduction of infectivity in the cell culture supernatants 
was observed with peptides 5and 29. The other 37 Gag- 
derived peptides showed no effect in this assay except 
peptide 9, which had toxic effects on cell cultures. In 
addition, peptide 21 was found to reduce the con- 
centration of infectious virus; however, this effect was 
not seen when the neighbouring overlapping peptides 
were tested and thus could not be correlated with a 
defined sequence. Therefore in all further experiments we 
focused our interest on peptides 4, 5, 28 and 29. 
Comparable results in the reduction of infectious virus 
were obtained when infected H9 cells were treated with 
the Gag-derived peptides. Only peptides 4, 5, 28 and 29 
were able to reduce the release of infectious virus. During 
treatment with the inhibiting peptides yncytium form- 
ation in primary infected cultures was only slightly 
reduced compared to the untreated controls indicating 
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Table 1. Amino acid sequences of peptides active in inhibition of HIVproduction in cell culture 
supernatants* 
HIV infectivity in peptide-treated 
cell culture supernatants 
RT activity (% of infectivity) 
Peptide concentration (lag/ml) 
Inhibitory 
Peptide Amino acid sequence 50 200 activity~ 
4 WASRELERFAVNPGLLETSEGCRQIL 588 (0-0%) 555 (0-0%) + + + 
5 NPGLLETSEGCRQILGQLQPSLQT 439 (0"0%) 489 (0.0%) + + + 
4 /5 ]  FAVNPGLLETSEGCRQIL 659 (0"0%) 446 (0.0%) + + + 
4/5m NPGLLETSEGCRQ 615 (0'0%) 1045 (0"5°/,) + + + 
4/5S LLETSEG 20482 (54'0%) 4474 (9"6%) + 
4/5a AAANPGLLETSEGCRQIL 1114 (0"6%) 1067 (0"5%) + + + 
4/5b$ FAVAAALLETSEGCRQI L ~ -~ 
4/5c FAVNPGAAATSEGCRQIL 43493 (100.0%) 1132 (0.7%) - 
4/5d FAVNPGLLEAAAGCRQIL 24088 (62'0%) 916 (0'1%) + 
4/5e FAVNPGLLETSEAAAQIL 11 386 (8"0 %) 7434 (17'5 %) + + 
4/5f FAVNPGLLETSEGCRAAA 21663 (55'0%) 847 (0'0%) + 
28 ANPDCKTILKALGPAATLEEMMTAC 399 (0"0%) 648 (0'0%) + + + 
29 AATLEEMMTACQGVGGPGHKARVLA 476 (0'0%) 667 (0"0%) + + + 
28/291 ALGPAATLEEMMTACQGV 455 (0"0%) 371 (0-0%) + + + 
28/29m PAATLEEHMTA 537 (0"0%) 390 (0"0%) + + + 
28/29s ATLEEMM 7546 (17-8%) 3278 (6.4%) ++ 
28/29a AAAPAATLEEHMTACQGV 847 (0"0%) 1335 (1"2%) + + + 
28/29b ALGAAATLEEMMTACQGV 1141 (0"7 %) 951 (0"I %) + + + 
28/2% ALGPAAAAAEMMTACQGV 20 103 (51"4°/,) 7917 (18"8 %) + 
28/29d ALGPAATLEAAATACQGV 52059 (100-0%) 20917 (53-9%) -- 
28/29e ALGPAATLEEMMAAAQGV 8498 (20.3 %) 14753 (37-1%) + + 
28/29f ALGPAATLEEMMTACAAA 1353 (1-3 %) 427 (0"0%) + + + 
Positive control (HIV-infected, not treated) 37418 (100 %) 
Negative control (not infected, not treated) 868 (0%) 
* The amount of infectious HIV was determined by analysis of RT activity ([aHlthymidine incorporation). The corresponding 
amount of infectious HIV was calculated using 100 % as equivalent to positive control (untreated, HIV-infected cultures, 0 lag 
peptide) and 0 % as equivalent to uninfected, untreated culture supernatant. 
t Inhibitory activity was estimated in the following way: + + +, 0 to 5 % infectious HIV (in relation to input virus 
concentration); + +, 5 to 30 % ; +, 30 to 60 % ; - ,  > 60 %. 
:~ Not tested, not soluble in PBS. 
that viral envelope proteins are synthesized and the 
CD4-gpl20 interaction mediating syncytium formation 
is not affected (data not shown). 
To characterize further the minimal number of amino 
acids responsible for the inhibitory activity we synthe- 
sized peptides panning the overlapping parts of the 
reactive compounds. Peptides were shortened from their 
amino and carboxy termini down to seven residues for 
peptides 4/5 and 28/29. Except for the smallest deriv- 
atives all peptides were able to inhibit the release of 
infectious HIV particles (Table 1). Hence the minimal 
length of the effective peptides could be mapped to 
amino acids 47 to 59 (NPGLLETSEGCRQ) and 339 to 
349 (PAATLEEMMTA) of the Gag sequence. 
After defining the minimal amino acid sequences 
necessary for inhibition of the production of infectious 
HIV-I we attempted to assign this effect to individual 
residues and functional amino acid side-chains. There- 
fore peptide derivatives of the shortened active com- 
pounds (4/51 and 28/291) were synthesized in which 
triplets of the original amino acid sequence were replaced 
by alanine. Alanine was chosen as it is a relatively small 
amino acid without functionally active groups in side- 
chains and therefore not known to induce major 
structural changes. Again the activity of these peptide 
compounds was measured by determination of RT 
activity in supernatants of indicator cell cultures. In all 
supernatants we found a reduction of RT activity using 
100 gg/ml or more of the peptide derivatives as com- 
pared to untreated controls. Some derivatives of peptide 
4/5 showed a total loss of inhibitory activity (peptide 
4/5c) at 50 lag/ml, when positions 50 to 61 (LLETSEG- 
CRQIL) were altered (Table 1). Peptide 4/5b could not 
be tested in this assay owing to problems with its 
solubility at the concentrations used. The data were even 
more consistent when the alanine-substituted peptide 
28/29 were used in cell culture systems: substitution of 
residues 342 to 350 (TLEEMMTAC) resulted in the loss 
of inhibitory activity at all concentrations (Table 1). 
Therefore we conclude that the region responsible for 
inhibition is located between amino acids 50 and 61 in 
the p17 and between 342 and 350 in the p24 sequences. 
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To determine whether the inhibitory effect could be 
overcome by the use of high virus concentrations we 
incubated the shortened forms of the active peptides 
4/5m and 28/29m at various concentrations with cells 
infected with up to 400 TCID~0 of HIV-1. Fifty gg/ml 
peptide concentrations were sufficient to inhibit the 
infectivity of high virus loads even when applied for a 
long period of 20 days (Fig. 1 c). In addition, this 
demonstrated that the peptides did not exert major toxic 
effects on the cell cultures and that the inhibitory effect of 
the peptides could not be washed out. Slight variations 
observed in RT activity in cells treated with different 
amounts of peptides are in the range of error intrinsic to 
this test system. All the values show that only very low 
amounts of infectious HIV (less than 0-5 % of the input 
virus; see Table 1) are detectable. 
To analyse further the effects that the peptides may 
have on HIV-infected cells and the production of 
infectious HIV-particles, and which step during the viral 
propagation cycle is affected, we subjected peptide- 
treated, HIV-l-infected Jurkat and H9 cells to thin 
section transmission electron microscopy (TEM). After 3 
days of treatment with the respective peptides, virus- 
infected Jurkat cells and chronically infected H9 cells, as 
well as non-treated infected and uninfected control cells 
were fixed with 2-5 % gtutaraldehyde and processed for 
TEM using standard techniques (Gelderblom et al., 
1987). After treatment with OsO4 the cells were enclosed 
in agarose blocks, treated with 1% tannic acid and, after 
dehydration, embedded in Epon. Ultrathin sections, 
approximately 50nm, were stained with lead citrate and 
evaluated using a Zeiss EM 10 A TEM. These experi- 
ments revealed that after treatment with the respective 
peptides particulate viral structures were formed at the 
surface of the cells. However the majority appeared to be 
immature or malformed and showed a tendency to 
remain associated with the cell surface. HIV-l-infected 
H9 cells treated with peptide 29 (40 Dg/ml medium) are 
shown in Fig. 2 as an example. No mature virus particles 
with conical capsid core structures budding from the 
surface of the cell could be found. Chronically infected 
H9 cultures or freshly infected Jurkat cells treated with 
the other reactive peptides showed similar effects in 
electron microscopy. 
We have described Gag-derived peptides that inhibit 
the release of infectious HIV particles from infected 
Jurkat and H9 cells. The mechanism by which the 
peptides may exhibit their inhibitory effect remains 
unclear at present. A similar peptide effect has been 
reported only by Collier et al. (1991) using compounds 
derived from influenza virus haemagglutinin protein 
sequences which reduce the formation of influenza virus 
particles. In our system, two Gag-derived peptide 
domains could be defined that inhibit the correct 
assembly of the viral components in the cell and the 
maturation process. One region could be aligned with 13 
residues of the matrix protein p 17 (amino acids 47 to 59), 
the second with 11 residues of the capsid protein p24 
(amino acids 339 to 349) (Table 1, Fig. 1). The peptide 
effect results in a drastic loss of infectivity of up to 100 %, 
and only immature particulate structures are released 
from the cell surface (Fig. 2). The observations that viral 
Gag proteins are synthesized as shown by electron 
microscopy and that viral envelope polypeptides are 
produced (as the treated cells are able to induce 
syncytium formation) exclude the possibility that early 
or regulatory steps are affected by the peptides. The 
release of morphologically distinct viral particles points 
to a step during virus assembly as the target. 
One of the late processes known to be affected by 
peptides i the maturation cleavage of the Gag precursor 
protein by the viral protease. Inhibition of the HIV- 
specific protease shows a similar immature virus to be 
released from the cell surface (Sch~itzl et al., 1991). 
Preliminary experiments did not show that the peptides 
found to be active in our test systems affect the activity 
of the viral protease. However, the peptides could alter 
the protein conformation i  such a way that correct 
interactions or proteolytic leavage into the mature 
proteins cannot be performed. There are indications by 
other groups (K. von der Helm, personal communi- 
cation) that conformational changes have to occur in 
Gag precursor proteins to allow successive r cognition of 
the individual proteolytic leavage sites. 
The peptides may display their activity in a different 
way. They may lower the concentration f Gag precursor 
proteins in the submembrane compartment, leading to 
incorrect budding. The electron microscopical observ- 
ations indicate that the observed effect occurs late in the 
viral replicative cycle. Incorrect budding could involve 
a mechanism similar to that described for the inhibition 
of herpesvirus-encoded ribonucleotide reductase by 
sequence-derived peptides (Dutia et al., 1986; Cohen et 
al., 1986; Gaudreau et al., 1990; Telford et al., 1990). 
These peptides represent protein interaction domains 
which inhibit the dimerization of the monomers necess- 
ary for enzyme activity. As shown by Trono et al. (1989), 
HIV-1 Gag mutants can interfere with the replication of 
wild-type virus. 
Recent results by our group using site-directed 
mutagenesis of residues TLEEM and CQG (von 
Poblotzki et al., 1993) have shown that this region is 
functionally active in Gag particle formation. The system 
used by von Poblotzki et al. is different to that used in 
this paper since all Gag proteins ynthesized in the cell 
are mutated, leading to complete blocking of the virus 
assembly process. In contrast, when peptides derived 
from that region are added to infected cultures the wild- 
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Fig. 2. TEM of HIV-l-infected H9 cells treated with peptide 29 (100 gg/ml). (a) H1V-l-infected H9 cell treated with peptide 29 for 3 
days; particulate structures similar to immature HIV are shed from the cell surface. Bar marker epresents 1 gin. (b) Magnification of
the particulate structures budding from HIV-l-infected H9 cells treated with peptide 29 showing malformed, immature particles. (c) 
Magnification of particulate structures budding from HIV-l-infected H9 cells without peptide treatment. These particles show the 
conical capsid core structure characteristic for mature, infectious HIV particles. Bar marker represents 100 nm and applies also to (b). 
type protein is hindered only in its normal function but 
is sufficiently active for induction of the budding process. 
Both gag regions are conserved in most HIV strains, 
particularly for the domain defined in p24. In addition 
there is a high degree of similarity in sequence to simian 
and feline immunodeficiency viruses suggesting that this 
region is functionally very important in virus assembly. 
The activity of HIV-l-derived peptides in suppression 
also of HIV-2 further emphasizes the independence of 
this region of gag, conserved between different isolates 
(M. Niedrig, unpublished results). Yu et al. (1992) also 
found, for the region active in p17, that amino acid 
deletions affect the release of HIV particles from the 
cells. 
The peptides used in our assays were not toxic for 
cells, unlike most protease inhibitors; this allows their 
potential use as therapeutically active compounds. In 
comparison to inhibitors of RT they should have the 
advantage that during their application immature virus 
particles are released from the cell and these could 
stimulate the immune system of the patient. 
As a first step towards designing therapeutically active 
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stable compounds, the individual residues active in the 
mechanism were identified by synthesis of alanine- 
modified peptides. Further modifications including the 
replacement of natural amino acids by other sequences 
would be necessary for the design of compounds with a 
long half-life and active in concentrations that can be 
given to patients. 
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